scispace - formally typeset
F

Fabien Zoulim

Researcher at French Institute of Health and Medical Research

Publications -  716
Citations -  40988

Fabien Zoulim is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Hepatitis B virus & Hepatitis B. The author has an hindex of 96, co-authored 641 publications receiving 35807 citations. Previous affiliations of Fabien Zoulim include Hotel Dieu Hospital & University of Orléans.

Papers
More filters
Journal ArticleDOI

Inhibition of the binding of HCV serum particles to human hepatocytes by E1E2-specific D32.10 monoclonal antibody.

TL;DR: An in vitro direct cell‐binding assay based on the attachment of radiolabeled HCVsp was developed, and Scatchard plots were used to analyze ligand–receptor binding data, which supports the involvement of the E1E2/D32.10 discontinuous antigenic determinant in the interactions between human hepatocytes andHCVsp, and suggests that D32.
Journal ArticleDOI

Performance of the cobas® HBV RNA automated investigational assay for the detection and quantification of circulating HBV RNA in chronic HBV patients.

TL;DR: For example, the Roche cobas® 6800/8800 analyzer as discussed by the authors was used for quantification of circulating hepatitis B RNA (cirB-RNA), which is a promising biomarker for monitoring antiviral treatment.
Journal ArticleDOI

CRISPR-Cas9 Targeting of Hepatitis B Virus Covalently Closed Circular DNA Generates Transcriptionally Active Episomal Variants

TL;DR: In this article , the fate of covalently closed circular DNA (cccDNA) was determined after gene editing with CRISPR-Cas9 and showed that the effects induced by Cas9 were sustainable after RNP degradation/loss of detection, suggesting permanent changes in the HBV genome instead of transient effects due to transcriptional interference.
Journal ArticleDOI

Reciprocal antagonism between the netrin-1 receptor uncoordinated-phenotype-5A (UNC5A) and the hepatitis C virus

TL;DR: While the UNC5A dependence receptor counteracts HCV persistence through regulation of autophagy in a DAPK-dependent manner, it is dramatically decreased in all instances in HCC samples, and specifically by HCV in cirrhosis.
Journal ArticleDOI

Benefit of direct-acting antiviral therapy for hepatitis C virus (HCV) in monoinfected and HIV-HCV-coinfected patients with mixed cryoglobulinaemia.

TL;DR: DAA-induced SVR allows cryoglobulin clearance in two-thirds of patients, and this therapy improves clinical outcome of HCV infection with sustained virological response rates above 90%.